The deal, slated to close in the coming months, values the two Idaho facilities at approximately $1.15 billion. While Surgery Partners expects the sale to generate a substantial cash infusion, the company has not yet disclosed the exact net proceeds. Management confirmed that current full-year guidance remains unchanged for the time being, though officials may revise those projections following the transaction's completion.

Investors are looking toward the company's upcoming quarterly earnings report, scheduled for August 10, for further clarity on how this divestiture fits into the broader corporate strategy. The sale represents a calculated step to consolidate resources and focus on core surgical operations amid evolving market demands.